NCT03932864 is a Phase 1 clinical trial of MGTA-145 in Healthy Volunteers, sponsored by Ensoma.

Who is sponsoring NCT03932864?

NCT03932864 is sponsored by Ensoma.

What drugs are being tested in NCT03932864?

Interventions in NCT03932864: MGTA-145, plerixafor, Placebo.

What condition does NCT03932864 study?

NCT03932864 studies Healthy Volunteers.

Is NCT03932864 still recruiting?

NCT03932864 is currently completed. Last updated 11 January 2024.

Last reviewed 2024-01-11 · How we verify

NCT03932864

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

Completed Phase 1 Last updated 11 January 2024

What this trial tests

Phase 1 trial testing MGTA-145 in Healthy Volunteers in 107 participants. Completed in 25 February 2020.

Timeline

22 April 2019

Primary endpoint
25 February 2020

25 February 2020

Quick facts

Lead sponsor	Ensoma
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	107
Start date	22 April 2019
Primary completion	25 February 2020
Estimated completion	25 February 2020
Sites	1 location across United States

Drugs / interventions tested

MGTA-145 — full drug profile →
plerixafor (plerixafor) — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Ensoma — full company profile →

Who can join

Adults 18 to 60, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145 in healthy volunteers as a single agent and in combination with plerixafor.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Hematopoietic Stem Cell Mobilization: Current Collection Approaches, Stem Cell Heterogeneity, and a Proposed New Method for Stem Cell Transplant Conditioning.
Menendez-Gonzalez JB, Hoggatt J. · · 2021 · cited 11× · PMID 34661830 · DOI 10.1007/s12015-021-10272-1
Mobilization-based engraftment of haematopoietic stem cells: a new perspective for chemotherapy-free gene therapy and transplantation.
Canarutto D, Omer Javed A, Pedrazzani G, Ferrari S, et al · · 2023 · cited 10× · PMID 37460391 · DOI 10.1093/bmb/ldad017
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang EC, Muffly LS, Shiraz P, Shizuru JA, et al · · 2021 · cited 9× · PMID 33775587 · DOI 10.1016/j.jtct.2021.02.026
The 46<sup>th</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706).
· 2020 · cited 6× · PMID 33311612 · DOI 10.1038/s41409-020-01120-w

Verify or expand the search:

Other trials of MGTA-145

Trials testing the same drug.

NCT05445128 — Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease · Phase 2 · terminated
NCT04762875 — MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies · Phase 2 · terminated
NCT04552743 — MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma · Phase 2 · completed
NCT04154670 — Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Ensoma trials

Trials by the same sponsor.

NCT05445128 — Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease · Phase 2 · terminated
NCT04762875 — MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies · Phase 2 · terminated
NCT04154670 — Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03932864 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ensoma
Last refreshed: 11 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03932864.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing